Attrition table of study patient population in phase I
Patient size by BM method | Breast cancer | NSCLC | Prostate cancer | |||
N | % | N | % | N | % | |
Eligible cohort at feasibility stage | 6142 | 100 | 5202 | 100 | 5382 | 100 |
Patient cohort identified with BM in the medical records | 573 | 9.3 | 899 | 17.3 | 1017 | 18.9 |
Patients identified by NLP of reports * | 527 | 92.0 | 829 | 92.2 | 963 | 94.7 |
Patients identified as receiving BTA treatment * | 309 | 53.9 | 118 | 13.1 | 129 | 12.7 |
Patients identified as patient having SCC * | 19 | 3.3 | 41 | 4.6 | 42 | 4.1 |
Patients identified in coded EMR field * | 49 | 8.6 | <75 | – | 55 | 5.4 |
Final cohort of patients with BM after further clinical review | 559 | 9.0 | 894 | 17.0 | 1013 | 18.8 |
*Number of patients identified as BM by each method of the overall eligible cohort and confirmed after review by two clinical physicians (patient can be identified in multiple methods).
BM, bone metastasis; BTA, bone-targeting agents; EMR, electronic medical record; NLP, natural language processing; NSCLC, non-small cell lung cancer; SCC, spinal cord compression.